Tvardi Therapeutics, Inc. Annual Report: A Plain-English Guide

I’ve put together this guide to help you understand Tvardi Therapeutics’ performance this year. My goal is to turn complex filings into clear information so you can decide if this company fits your investment goals.

1. What does this company do?

Tvardi Therapeutics is a clinical-stage biotech company. They research and develop small-molecule inhibitors of STAT3, a protein that drives cancer and inflammation. Their lead drug, TTI-101, is an oral medication currently in Phase 2 trials for advanced solid tumors and idiopathic pulmonary fibrosis (IPF). Because they are still in the research phase, they earn no money from product sales. Instead, we measure their success by how quickly they enroll patients in trials, their clinical data results, and their "cash runway"—how long they can operate before running out of money.

2. A Major Transformation: The Merger

The biggest news this year is a major corporate shift. In April 2025, Tvardi completed a reverse merger with Cara Therapeutics. The combined company now operates as Tvardi Therapeutics, Inc. To meet Nasdaq listing requirements, they executed a 1-for-3 reverse stock split, which consolidated the number of shares. This merger gave Tvardi a public listing and a cash boost from Cara’s balance sheet, which is vital for funding their TTI-101 and TTI-109 programs.

3. Financial Health: The "Going Concern" Warning

Tvardi is in a "spending to grow" phase, meaning they have high research costs and no income. They reported a loss of roughly $45 million for the fiscal year, with about $32 million in cash on hand. Auditors have raised "substantial doubt" about the company’s ability to stay in business because their current cash won't cover operations for the next 12 months. To keep going, they must raise more money through selling shares, taking on debt, or finding partners. These options are never guaranteed and depend on unpredictable market conditions.

4. Major Wins and Challenges

The company’s value depends entirely on its drug candidates, TTI-101 and TTI-109. TTI-101 has shown early promise in treating liver cancer patients who didn't respond to other therapies. However, they still need to prove the drug works in larger, more rigorous trials. Drug development is risky; even with good early data, a single failed trial could lead to a total loss for shareholders because the company has no other approved products to fall back on.

5. Key Risks

The biggest risk is the "all-or-nothing" nature of drug development. Since they have no revenue, Tvardi relies entirely on outside investors. If they cannot raise money at good prices, they may have to issue many new shares. This would reduce your ownership percentage and the value of your current holdings. They also face stiff competition from major pharmaceutical companies with massive budgets. If a competitor brings a similar drug to market first, Tvardi’s future could be in jeopardy.

6. Future Outlook

The road ahead depends on upcoming clinical milestones. Watch for data readouts for TTI-101 in late 2025 and early 2026. Success here is the only way to secure partnerships with large pharmaceutical companies or eventually bring a product to market. Without a major clinical win or a partnership, the company will remain under extreme financial pressure and will likely need to keep raising money to survive.

How to use this information: When considering an investment in Tvardi, ask yourself if you are comfortable with the high-risk nature of early-stage biotech. Because the company is currently burning cash to fund its research, your investment is essentially a bet on the success of their clinical trials. If you decide to move forward, keep a close eye on their quarterly updates regarding their cash balance and any announcements about new funding or clinical trial results.